Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 10/20 | 0.61 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FPR3 | P25089 | 1/20 | 0.39 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 2/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7000468 | 0.87 | CCR1 (0.47) | CCR1TSHRFPR3GPR65GPR35 | |
| SCHEMBL6157931 | 0.87 | CCR1 (0.57) | CCR1PTGER4TSHRFPR3GPR65 | |
| SCHEMBL7000678 | 0.85 | CCR1 (0.50) | CCR1TSHRFPR3GPR65GPR35 | |
| SCHEMBL6998823 | 0.83 | CCR1 (0.46) | CCR1TSHRFPR3GPR65GPR35 | |
| SCHEMBL6996406 | 0.83 | CCR1 (0.42) | CCR1TSHRFPR3GPR65GPR35 | |
| SCHEMBL6993640 | 0.81 | CCR1 (0.59) | CCR1FPR3GPR65GPR35HTR4 | |
| SCHEMBL7001038 | 0.80 | MEN1 (0.45) | CCR1TSHRFPR3GPR65GPR35 | |
| SCHEMBL6761988 | 0.79 | CCR1 (0.49) | CCR1PTGER4TSHRFPR3GPR65 | |
| SCHEMBL6761986 | 0.79 | CCR1 (0.49) | CCR1PTGER4TSHRFPR3GPR65 | |
| SCHEMBL6761312 | 0.79 | CCR1 (0.48) | CCR1PTGER4TSHRCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326867-A2 | BRIDGED PIPERAZINE DERIVATIVES | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020119961-A1 | Bridged piperazine derivatives | PFIZER INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002032901-A2 | BRIDGED PIPERAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119961-A1 | Bridged piperazine derivatives | MYD88, IL4, ARG1 | CCR1 7/4885PTGER4 1468/4885TSHR 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.